Aurobindo Pharma Limited — Important, 11-04-2025: General Updates

The US FDA has completed its inspection of the Raleigh Plant in North Carolina, operated by Aurolife Pharma LLC, a wholly owned subsidiary of Aurobindo Pharma. The inspection took place from late March to early April and resulted in a Form 483 with 11 procedural observations. The company plans to submit a comprehensive response addressing each observation with corrective actions. Importantly, Aurobindo does not anticipate any material impact on its current operations or the supplies originating from this facility. This situation reflects the company's commitment to quality and compliance, which should be noted as a stable factor for stakeholders. Watch closely as they follow up with the FDA on these observations.